Fusion Antibodies PLC Director/PDMR Shareholding (4728Z)
10 Gennaio 2020 - 12:47PM
UK Regulatory
TIDMFAB
RNS Number : 4728Z
Fusion Antibodies PLC
10 January 2020
10 January 2020
Fusion Antibodies plc
("Fusion" or the "Company")
Director/PDMR Shareholding
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical
antibody discovery, engineering and supply for both therapeutic
drug and diagnostic applications, has been notified today that, on
8 January 2020, Alan Mawson, Non-Executive Director, purchased
20,000 ordinary shares in the Company ("Ordinary Shares") into his
pension fund at a price of 77 pence per Ordinary Share.
Following this purchase, Alan Mawson has a direct and indirect
interest in 108,988 Ordinary Shares, representing approximately 0.5
per cent. of the Company's issued share capital. Alan Mawson is
also a Non-Executive Director of Clarendon Fund Managers Limited
("Clarendon") and sits on Clarendon's investment committee.
Clarendon is the fund manager for Nitech Growth Fund LP which holds
358,850 Ordinary Shares and Viridian Growth Fund LP which holds
1,831,500 Ordinary Shares.
The following notification, made in accordance with the
requirements of the EU Market Abuse Regulation, gives further
details.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Alan Mawson
------------------------ ---------------------------------------
2 Reason for the notification
-----------------------------------------------------------------
a) Position/status Non-Executive Director
------------------------ ---------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------ ---------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------
a) Name Fusion Antibodies plc
------------------------ ---------------------------------------
b) LEI 213800KBAYRC9VOQ9V39
------------------------ ---------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------
a) Description Ordinary shares of 4p each in Fusion
of the financial Antibodies plc
instrument, Identification code (ISIN) for Fusion
type of instrument Antibodies plc ordinary shares:
Identification GB00BDQZGK16
code
------------------------ ---------------------------------------
b) Nature of the Purchase of shares
transaction
------------------------ ---------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) 77p 20,000
----------
------------------------ ---------------------------------------
d) Aggregated information: N/A
- Aggregated
volume
- Price
------------------------ ---------------------------------------
e) Date of the 8 January 2020
transaction
------------------------ ---------------------------------------
f) Place of the London Stock Exchange, XLON
transaction
------------------------ ---------------------------------------
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Dr Paul Kerr, Chief Executive Officer Via Walbrook PR
James Fair, Chief Financial Officer
Allenby Capital Limited Tel: +44 (0)20 3328 5656
James Reeve / Asha Chotai
Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Fusion Antibodies plc - www.fusionantibodies.com
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the
development of antibodies for both therapeutic drug and diagnostic
applications.
The Company's ordinary shares were admitted to trading on AIM on
18 December 2017. Fusion provides a broad range of services in
antibody generation, development, production, characterisation and
optimisation. These services include antigen expression, antibody
production, purification and sequencing, antibody humanisation
using Fusion's proprietary CDRx(TM) platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced and expressed over 250 antibodies and successfully
completed over 150 humanisation projects for its international,
blue-chip client base, which has included eight of the top 10
global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's
University Belfast. The Company's mission is to enable
pharmaceutical and diagnostic companies to develop innovative
products in a timely and cost-effective manner for the benefit of
the global healthcare industry. Fusion Antibodies provides a broad
range of services in antibody generation, development, production,
characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the
latest technological advances with cutting edge science to deliver
new platforms that will enable Pharma and Biotechs get to the
clinic faster and ultimately speed up the drug development
process.
The global monoclonal antibody therapeutics market was valued at
$95.5 billion in 2017 and is forecast to surpass $174.2 billion in
2026, an increase at a CAGR of 6.9 per cent. for the period 2018 to
2026. In 2018, seven of the world's ten top selling drugs were
antibody-based therapeutics with the combined annual sales of these
drugs exceeding $62 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHSFIFFSESSELF
(END) Dow Jones Newswires
January 10, 2020 06:47 ET (11:47 GMT)
Grafico Azioni Fusion Antibodies (LSE:FAB)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Fusion Antibodies (LSE:FAB)
Storico
Da Mar 2023 a Mar 2024